Stock Watch: GLP-1 Expectations Dashed
Pfizer’s Foray Into Obesity Slims Down As Tolerability Becomes The New Battleground
If oral GLP-1 agonists are going to be successful in a wider weight loss indication, lower efficacy may be the trade-off for better tolerability in this bigger and more healthy population.
